<DOC>
	<DOCNO>NCT00639743</DOCNO>
	<brief_summary>Heparin reference therapy patient pulmonary embolism . Some patient sub-massive pulmonary embolism define normal blood pressure dysfunction right ventricle high mortality risk . It suggest thrombolytic treatment , drug dissolve blood clot rapidly , may reduce mortality patient . The study report date unable confirm refute hypothesis number patient include study low . The aim study compare thrombolytic treatment heparin ( reference therapy pulmonary embolism ) large group patient sub-massive pulmonary embolism .</brief_summary>
	<brief_title>PEITHO Pulmonary Embolism Thrombolysis Study</brief_title>
	<detailed_description>A prospective , randomize , double-blind , placebo-controlled , international , multicentre , parallel-group comparison trial evaluate efficacy safety single i.v . bolus tenecteplase plus standard anticoagulation compare standard anticoagulation normotensive patient acute pulmonary embolism echocardiographic laboratory evidence right ventricular dysfunction.Patients suffer acute pulmonary embolism ( first symptom occur within 15 day ) confirm lung scan positive spiral compute tomogram , positive pulmonary angiogram , present right ventricular dysfunction echocardiography test troponin I T positive include study exclusion criteria.Patients investigational group receive : Ø Tenecteplase single body-weight ( know estimate ) adjust IV bolus administer 5 - 10 second later 30 minute randomization , later 2 hour diagnosis RV dysfunction Weight ( kg ) Dose mg Dose unit Dose ml &lt; 60 30 mg 6000 U 6 ml &gt; 60 &lt; 70 35 mg 7000 U 7 ml &gt; 70 &lt; 80 40 mg 8000 U 8 ml &gt; 80 &lt; 90 45 mg 9000 U 9 ml &gt; 90 50 mg 10000 U 10 mlØ : concomitant therapy-Unfractionated heparin dose 80 IUxKg-1 intravenous bolus , follow infusion 18 IUxKg-1xh-1 , administer immediately randomization patient least 48 hour follow randomization . Beyond period , intravenous UFH may substitute subcutaneous heparin ( LMWH ) treatment . The bolus omit heparin start randomisation.Patients control group receive Ø placebo single body-weight ( know estimate ) adjust IV bolus administer 5 - 10 second later 30 minute randomization , later 2 hour diagnosis RV dysfunction . Weight ( kg ) Dose ml &lt; 60 6 ml &gt; 60 &lt; 70 7 ml &gt; 70 &lt; 80 8 ml &gt; 80 &lt; 90 9 ml &gt; 90 10 mlØ concomitant therapy Unfractionated heparin</detailed_description>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Tenecteplase</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Age 18 year old Acute PE ( first symptom occur 15 day less randomisation ) confirm lung scan , positive spiral compute tomogram , positive pulmonary angiogram Right ventricular dysfunction confirm echocardiography spiral compute tomography chest positive troponin I T test Exclusion criterion : Haemodynamic collapse presentation define Known significant bleeding risk Administration thrombolytic agent within previous 4 day Vena cava filter insertion pulmonary thrombectomy within previous 4 day Uncontrolled hypertension define systolic BP &gt; 180 mm Hg and/or diastolic BP &gt; 110 mm Hg randomisation Treatment investigational drug another study protocol previous 7 day great , accord local requirement Previous enrolment study Known hypersensitivity tenecteplase , alteplase , unfractionated heparin , excipients Pregnancy , lactation parturition within previous 30 day . Women childbearing age must negative pregnancy test use medically accept method birth control Known coagulation disorder ( include vitamin K antagonist ) Any condition investigator feel would place patient increase risk investigational therapy initiate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Pulmonary embolism</keyword>
	<keyword>Heparin</keyword>
	<keyword>Thrombolytic therapy</keyword>
	<keyword>Bleeding</keyword>
</DOC>